2014 FFM Friends Day speakers

Posted on 08-04-2014

Discover here the curiculum vitae of the 2014 FFM Friends Day speakers.

Philippe Coucke

Dr Philippe Coucke

Dr Philippe Coucke is born in Ghent in 1959. He accomplished his medical degree at the Sate University of Ghent Belgium in 1984 and started his training in radiation oncology at the same university hospital. He moved from Ghent to Besançon in France in 1987 to finish his training as a radiation oncologist. He was board certified in radiation oncology in 1988 and worked in Besançon as junior member of the staff for one more year.

From 1989 on, he became senior member of the staff at the University Hospital in Lausanne (CHUV), Switzerland. In 1996, he obtained the Academical degree of “Privat Docent & Maître d’Enseigment et de Recherche” at this same university. He has been active in radiation biology research (especially in the following fields: importance of human tumour cell kinetics, sensitizing human tumour cells to ionizing irradiation especially with halogenated nucleosides in vitro and in vivo) and in clinical research (especially in the following fields: changes in fractionation pattern in radiotherapy for rectal cancer, stereotactic cranial irradiation, endovascular brachytherapy to prevent ins-stent restenosis). He was also trained in managerial skills at CHUV and made a thesis on “organisational learning and resistance to change”.  He left Switzerland in 2005 and became head of the department of radiotherapy at Hopital Maisonneuve Rosemont, Montreal Canada. He was appointed as clinical professor at the University of Montreal.  In 2006, he came back to Belgium to become head of the department of radiotherapy at the University Hospital in Liège and Professor of Radiation Therapy at the same university.

His interest is focused nowadays on breast cancer and especially changes in fractionation patterns (hypo-fractionation and simultaneous integrated boost) and prone positioning for breast irradiation (he developed the Sagittilt® and obtained a European licence).

In his department, he launched a small radiation biology group working together with GIGA-Cancer (effect of preoperative radiation on metastatic potential). His group is also active in implementing metabolic imaging in treatment planning and sensing of treatment effects (collaboration with the cyclotron in Liège). He installed in 2009 the first totally dedicated linear accelerator in Belgium for real time tumour tracking during irradiation (CyberKnife). He has also been granted 4 times by MWQ (Mouvement Wallon pour la Qualité) for the application of the EFQM excellence model (European foundation for Quality Management) in his department. He is conducting managerial research in collaboration with HEC-Liège.
He is author and co-author of 131 publications in peer-reviewed journals, wrote 50 papers in non-indexed journals and 7 chapters in books.


Steven Joniau

Dr Steven Joniau

Dr Steven Joniau graduated in Urology in 2002 at the Catholic University of Leuven. In 2003, he was appointed full-time staff member at the Dept of Urology, University Hospitals Leuven after a 1-year fellowship at the University Hospital of Wales, Cardiff, UK. In July 2012, he obtained his PhD in Medical Sciences entitled ‘High-risk localized prostate cancer: the role of surgery and the development of clinical outcome prediction models’. In 2013, he was appointed Assistant Professor at the Catholic University of Leuven.

His principal field of interest is the management of urological cancers. He is heavily involved in uro-oncological surgery and the multidisciplinary approach of pelvic cancers. He also leads numerous research projects at the University Hospitals Leuven, which focus on lymph node staging in prostate cancer, surgical management and biomarker development of high-risk prostate cancer, the natural history of premalignant lesions of the prostate, chemoprevention of prostate and bladder cancer, minimally invasive treatment of renal cell cancer and prostate cancer, etc.

Dr Joniau is member of 6 editorial boards of peer reviewed journals and has served- or is serving as board- and or (program)committee member in several professional organizations such as EAU, SIU, SIOG and EORTC GUCG.

Steven Joniau has received several international awards and, in the last 10 years, he has published more than 145 papers in peer-reviewed journals in the field of uro-oncology and minimally invasive surgery. He authored several book chapters, he has been invited Faculty in over 75 international congresses and is a faculty member of the ESU (European School of Urology).

Jaak Schalken

Dr Jack Schalken 

Dr Jack Schalken was trained as biochemist at the Radboud University Nijmegen, where he also obtained his PhD degree (1987). He did his post doctoral fellowship at Johns Hopkins Hospital (Baltimore, MD). He is director of urological research at the Radboud University Medical Center (1986-now). In 1996 Dr Schalken was appointed as  professor of experimental oncology at the University of Utrecht. Since 2001 he is professor of experimental urology at the Radboud University (Nijmegen).

His research has a strong translational component, i.e. conducting life sciences research to accelerate healthcare outcomes, specific themes
1. Unravelling the mechanism of GU cancer invasion/cadherin switching/EMT
2. Cancer stem/initiating cells
3. Targeted therapy in (GU) cancer
4. Molecular diagnostics of prostate cancer (eg PCA3)
5. Combining 1 thru 4 to make steps towards personalized medicine
Dr Schalken is member of 12 editorial boards of peer reviewed journals and has served- or is serving as board- and or (program)committee member in several professional organizations such as ESUR, SBUR, EAU, ASCO and ESMO.
Dr Schalken is (co)author on more than 325 peer reviewed publications, 74 book chapters and has edited 10 books/special journal issues. He supervised 32 completed PhD theses. He is inventor on approximately 20 patent applications (some still pending approval).

Dr. Manuela Joore

Dr Manuela Joore 

Dr Manuela Joore is associate professor at the Maastricht University Medical Centre’s department of ‘Clinical Epidemiology and Medical Technology Assessment’. She holds a MSc in Health Sciences/ Epidemiology (1996) and a PhD in Economics (2002; both from Maastricht University).

For 15 years Manuela Joore has been working in the field of Health Technology Assessment, in clinical areas including cardiovascular disease, oncology, pulmonology, mental health, urology and audiology. Her chief current research efforts are directed towards using (mostly) model-based health economic evaluation to inform policy decision making regarding pharmaceuticals, diagnostics and other health care technologies. She has a special methodological interest in the appropriate handling of uncertainty and heterogeneity in model-based health economic evaluations and how this information should be communicated to decision makers. Another methodological focus is on the conceptualisation and measurement of the benefits in health economic evaluation. For these methodological interests she was awarded in total five methodological research grants and an implementation grant in the past six years. Furthermore, Manuela Joore is actively involved in the process of health care policy decision making, both nationally (member of the Scientific Advisory Committee, subcommittee Pharmaceuticals, Health Care Insurance Board) and internationally (she leads the group of researchers in Maastricht who undertake a series of technology assessment reviews for the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom).

Manuela Joore is/was the co-supervisor of over a dozen Ph.D. students. She has (co-) authored more than 80 international scientific papers in peer reviewed international journals, which include journals such as The Lancet, Journal of Clinical Oncology, Value in Health, Pharmacoeconomics, the Annals of Internal Medicine, Thorax, and Medical Care. The total number of national and international grants obtained as a (co-)applicant adds up to more than 30 with a total sum of more than 13 million Euros.

Cathy Clerinx

Cathy Clerinx

Cathy’s professional career has revolved entirely around the art and science of ‘listening to the customer’ in the global healthcare sector. After completing her studies in economics in the mid-eighties, she joined Mc Neil Pharmaceuticals, a J&J company in the USA, where she built long-term forecasts and for in-licensing candidates and new products in early development.  She realized very quickly that such forecasts are only as good as its assumptions, many of which are based on having a good understanding of the views of (potential) customers of your product or concept.  

As a result, Cathy’s focus shifted to the broader field of market research and customer insights.  She held various international positions at J&J, GSK and Novartis, supporting early development decisions, and preparing the launch of brands such as Topamax (an antiepileptic), Retrovir (the first antiviral for HIV), Exelon (for Alzheimer’s disease).   During these years, she commissioned a wide number of qualitative and quantitative research projects to ensure the end-customer’s view was heard among marketing, medical and scientific colleagues.

In 1994, she joined a small market research consultancy, Adelphi, which grew to become one of the leading international research agencies in the healthcare sector.  She directed over 200 research projects on behalf of her clients, using both qualitative and quantitative market research methods.  In this role, she conducted a large number of interviews and focus groups with patients, healthcare professionals, caregivers, and ‘payers’.

In 2009, she founded AX’S Consulting together with 2 partners.  AX’S Consulting provides its clients with clear insights on the market access environment in Europe: who are the stakeholders involved in the decision to grant reimbursement and access for new products to patients, what are their needs and perspectives, how can you show value of your products.